Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-802
Authors: Breuksch, Ines
Welter, Jonas
Bauer, Heide-Katharina
Enklaar, Thorsten
Frees, Sebastian
Thüroff, Joachim W.
Hasenburg, Annette
Prawitt, Dirk
Brenner, Walburgis
Title: In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself
Online publication date: 6-Aug-2018
Year of first publication: 2018
Language: english
Abstract: BACKGROUND: Loss of PTEN is involved in tumor progression of several tumor entities including renal cell carcinoma (RCC). During the translation process PTEN generates a number of splice variants, including PTEN-Δ. We analyzed the impact of PTEN-Δ in RCC progression. METHODS: In specimens of RCC patients the expression of PTEN-Δ and PTEN was quantified. The PTEN expressing RCC cell line A498 and the PTEN deficient 786-O cell line were stably transfected with the PTEN-Δ or PTEN transcript. In Caki-1 cells that highly express PTEN-Δ, this isoform was knocked down by siRNA. Cell migration, adhesion, apoptosis and signaling pathways activities were consequently analyzed in vitro. RESULTS: Patients with a higher PTEN-Δ expression had a longer lymph node metastasis free and overall survival. In RCC specimens, the PTEN-Δ expression correlated with the PTEN expression. PTEN-Δ as well as PTEN induced a reduced migration when using extracellular matrix (ECM) compounds as chemotaxins. This effect was confirmed by knockdown of PTEN-Δ, inducing an enhanced migration. Likewise a decreased adhesion on these ECM components could be shown in PTEN-Δ and PTEN transfected cells. The apoptosis rate was slightly increased by PTEN-Δ. In a phospho-kinase array and Western blot analyses a consequently reduced activity of AKT, p38 and JNK could be shown. CONCLUSIONS: We could show that the PTEN splice variant PTEN-Δ acts similar to PTEN in a tumor suppressive manner, suggesting synergistic effects of the two isoforms. The impact of PTEN-Δ in context of tumor progression should thus be taken into account when generating new therapeutic options targeting PTEN signaling in RCC.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-802
URN: urn:nbn:de:hebis:77-publ-584125
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: Cell communication and signaling
16
Pages or article number: Art. 35
Publisher: BioMed Central
Publisher place: London
Issue date: 2018
ISSN: 1478-811X
Publisher URL: http://dx.doi.org/10.1186/s12964-018-0247-9
Publisher DOI: 10.1186/s12964-018-0247-9
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
58412.pdf1.82 MBAdobe PDFView/Open